F Hoffman-La Roche Ltd v Cipla Ltd Expert Analysis

By Shwetasree Majumder

Opening Remarks

The Hoffman La Roche/Cipla case was played out in far greater detail in the public domain than in the courts, right from the start. With all the attenti



September 29, 2012 - 3:14pm

Wow seriously! ............... ... At best of some casual academic use maybe.



September 22, 2012 - 2:51pm

Surprising that the author has been called a 'patent litigator'! The author apparently hardly does patent part of IP. An academic analysis maybe but not a practitioner's certainly.



September 22, 2012 - 1:46pm

[Edited] what is the ratio and decidendi based on which the court came to its conclusion. Mere reporting the judgement is of no use, everyone can do it. What is your view and the conclusions should be clearly stipulated. [Edited]



September 19, 2012 - 10:49pm

Brilliant extract, Shwe. Section 8 poses many questions and I wonder how the judgement did not take this into consideration as violation of provisions laid down in section 8 doubly locks the wrong doer.


Dr. Prashant Singh

September 19, 2012 - 6:33pm

Bayer and Roche defeat will impact long on indigenous and foreign drugmakers in coming future. In my views, Sec-3(d) is good for Indian peoples. Really good analysis. Keep it up Mam. Regards

B&B Newsletter

Keep with the times...

Subscribe to B&B Newsletter feed

Latest Tweets

Latest Tweets

A Day in the Life of a Transactional Lawyer




Follow us on